// App-Quantinova.ai

4223 : Combination therapy of BCR-ABL-positive B cell acute lymphoblastic leukemia by tyrosine kinase inhibitor dasatinib and c-Jun N-terminal kinase inhibition

Researchers

Presenter

  • Xinhua Xiao

Principal Investigators

  • Bo Jiao

  • Ruibao Ren

Medical Centers

  • Shanghai Institute of Immunology, Shanghai, China

Locations

  • China

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Acute lymphoblastic leukemia

  • Chronic Myelogenous Leukemia

  • B lymphoblastic leukemia

  • B-cell acute lymphoblastic leukemia

Biomarkers

  • Breakpoint Cluster Region

  • Ph chromosome

  • c-Jun N-terminal kinase

Drug/Treatment

  • dasatinib

  • L-Tyrosine

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved